Our experienced team of legal practitioners, who are recognized leaders in their respective fields, advises you on all areas of the Life Sciences sector. Dentons’ extensive global presence guarantees you an effective handling of all kinds of cross-border matters.

Key service areas

We support you in all legal matters relating to:

• M&A transactions, PE transactions
• License agreements, agreements for R&D cooperations and transfer of technologies
• Structuring and financing of emerging companies 
• Acquisition, use and enforcement of intellectual property rights and know-how
• Regulatory issues (clinical trials, marketing authorizations, certifications, production, distribution)
• Product-related issues (biosimilars, doublets, companion diagnostics, orphan drugs)
• Classification issues and “product-switches”
• Product marketing (law on health care advertising) 
• Employee inventions
• Antitrust matters 
• Representation in court proceedings, arbitration procedures and mediation

Among our clients are international and domestic companies in the pharmaceutical, diagnostic and medical devices industry as well as in the field of biotechnology.

Insights

Extension of MDR transition periods

March 27, 2023

On 16 February 2023, the EU Parliament extended the deadlines for certifying medical devices under the European Medical Device Regulation (2017/745, “Medical Device Regulation”—MDR) to prevent massive bottlenecks in the certification process and to mitigate the risk of shortages.

Changes in the prescribability of cannabis products

March 24, 2023

Germany: Last week, the G-BA decided to amend the German Medicinal Products Guideline (Arzneimittelrichtlinie – “AM-RL”). The newly adopted regulations of the G-BA already largely reflect the requirements of Section 31 VI of the German Social Code V (Sozialgesetzbuch V – “SGB V”), which allows the G-BA to provide the framework for further regulations on the granting of treatment.

Fund-raising document landscape in USA, Germany and Singapore

July 14, 2022

Singapore: The authors, from Dentons’ firms in Singapore and Germany, seek to provide a cross-border comparison of equity-related transactions documents often used in fund-raising transactions in USA, Germany and Singapore. The authors hope this can provide initial guidance to investors and founders of early-stage entities to better understand the legal documentation involved in an investment transaction in each of these countries.

News and Events

Recent Press Releases

Dentons advises atai Life Sciences on US$ 175 million venture debt financing

August 16, 2022

Global law firm Dentons, together with Latham & Watkins US, has advised clinical-stage biopharmaceutical company atai Life Sciences ("atai") on the closing of a venture debt loan facility of up to US$175 million with Hercules Capital. Under the terms of the agreement, US$15 million was drawn at closing, with an additional US$20 million available to be drawn at atai’s option by March 15, 2023, and thereafter, an additional US$25 million available to be drawn by December 15, 2023. The remaining US$115 million becomes available in tranches through March 31, 2025, subject to the satisfaction of certain conditions.

Dentons advises EU Malaria Fund on venture debt financing for biotech company Sanaria

November 11, 2020

Global law firm Dentons has advised the Berlin-based EU Malaria Fund on a venture financing deal with the biotech company Sanaria. As part of the transaction, Sanaria will receive a venture loan for the development of two malaria vaccines, a malaria therapeutic and an oral COVID-19 vaccine.

Dentons advises biotech company Pluristem on European Investment Bank financing

May 5, 2020

Global law firm Dentons has advised the Israeli biotech company Pluristem on a €50 million loan provided by the European Investment Bank (EIB). The financing is part of a cooperation agreement between the EIB and the Israel Innovation Authority, which aims to strengthen Israeli-EU cooperation in innovative research in the field of biotech, pharmaceutical research and public health.

View all press releases for Life Sciences in Germany